Head-to-head dispatch
Gala Health vs NowPatient
Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.
Desk Score
A women's desk that pairs a genuine brand-name Ozempic path with low compounded pricing in all 50 states — every rate of which is a yearly subscription.
Marked down on: No month-to-month price is published anywhere — the $179/mo headline sits directly above “All doses included. Yearly subscription.”, the $149 microdose tier carries the same term, and the FAQ quotes a third figure at “$199 per month (with a 3-month plan)”
Desk Score
NowPatient is a US-UK telehealth platform offering brand-name GLP-1 weight management access including Mounjaro, Wegovy (injection and oral tablet), and Saxenda.
Marked down on: Cash-pay pricing tracks full brand list price (~$1,000–$1,350/mo)
Gala Health takes this head-to-head with the higher Desk Score, 82/100 (B−) against 59/100 (C) for NowPatient. NowPatient still holds its ground where its strengths line up with yours.
Desk Score, dimension by dimension
Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.
Gala Health
82/100
B−
NowPatient
59/100
C
Price transparency
State access
Molecule range
Onboarding speed
Support responsiveness
Licensing & trust
The spec sheet
| Field | Gala Health | NowPatient |
|---|---|---|
| Semaglutide | $1,299/mo (brand Ozempic) | $1,349/mo (brand Wegovy) |
| Tirzepatide | $179/mo (yearly subscription) | $1,069/mo (brand Mounjaro, promotional rate) |
| Coverage | All 50 states | Coverage not published |
| Brand-name | Yes | Yes |
| Oral option | Injectable only | Yes |
| Best for | Women ready to commit to a year up front, who want a low compounded rate with a real brand-name Ozempic option on the same account. | Readers who want brand-name GLP-1 access without a compounded route. |
| Desk Score | 82/100B− | 59/100C |
The verdict
Desk pick — Gala HealthGala Health takes this head-to-head with the higher Desk Score, 82/100 (B−) against 59/100 (C) for NowPatient. NowPatient still holds its ground where its strengths line up with yours.
Choose Gala Health if…
Women ready to commit to a year up front, who want a low compounded rate with a real brand-name Ozempic option on the same account.
$1,299/mo (brand Ozempic) sema · $179/mo (yearly subscription) tirz · All 50 states
Choose NowPatient if…
Readers who want brand-name GLP-1 access without a compounded route.
$1,349/mo (brand Wegovy) sema · $1,069/mo (brand Mounjaro, promotional rate) tirz · Coverage not published
Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we file on a provider reads the same either way. Read full breakdowns: Gala Health · NowPatient.
Also here
CoreAge Rx tops every dispatch at 94/100
Whichever of these two you lean toward, the Desk's #1-rated provider outscores them both. The Desk's top dispatch: flat all-in pricing, both molecules, all 50 states — no teaser-rate traps.
More head-to-heads
- Gala Health vs CoreAge Rx
- NowPatient vs Vaylen
- Gala Health vs Strut Health
- NowPatient vs Ondra Health
- Gala Health vs Invigor Medical
- NowPatient vs Vytora Health
Or see the full comparison hub and the complete ranking.
Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.